Pacific Channel invests $500,000 in New Zealand-based InsituGen, a company developing innovative steroid hormone testing technology, as part of a $4 million investment round targeting expansion in veterinary diagnostics.

Target Company Overview

InsituGen, based in New Zealand, is at the forefront of innovation within the steroid hormone testing market. Its advanced technology enables rapid and precise identification of androgenic and estrogenic activities, setting the stage for a multi-test diagnostics platform aimed at assessing steroid hormone function. The company's unique, multi-patented bioassays are designed to detect the activation of androgen and estrogen receptors by both known and unknown compounds, including hormone-related substances and designer drugs.

Among its applications, InsituGen is developing hormone profiling for companion animals, specifically dogs and cats, which is crucial for monitoring general health. Abnormal hormone levels can lead to various health issues, such as hair loss, osteoporosis, and even tumours, making reliable testing essential for ensuring the longevity and quality of life for pets. This in-house testing solution is not only valuable for pet owners but also aligns with the increasing demand in the pet care market.

Industry Overview in New Zealand

The veterinary diagnostics industry in New Zealand is experiencing significant growth, catalyzed by factors such as rising pet ownership and increased awareness of animal health and wellnes